Remibrutinib shows significant complete response rates across 3 chronic inducible urticaria subtypes in the phase 3 RemIND trial.
Real-world study results showed that sonidegib was associated with greater treatment persistence than vismodegib at 12 months among adults with BCC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results